Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22775016 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1KMT2ALMNATSHR | |
| SCHEMBL20574016 | 0.87 | CYP1A2 (0.40) | SMN1; SMN2MEN1KMT2ALMNATSHR | |
| SCHEMBL26923742 | 0.87 | TSHR (0.39) | SMN1; SMN2MEN1KMT2ALMNATSHR | |
| SCHEMBL22609473 | 0.85 | TSHR (0.38) | MEN1KMT2ATSHRL3MBTL1CYP1A2 | |
| SCHEMBL998277 | 0.85 | TSHR (0.48) | SMN1; SMN2MEN1KMT2ALMNATSHR | |
| SCHEMBL20840269 | 0.85 | TSHR (0.48) | SMN1; SMN2MEN1KMT2ALMNATSHR | |
| SCHEMBL13738486 | 0.85 | TSHR (0.48) | SMN1; SMN2MEN1KMT2ALMNATSHR | |
| SCHEMBL13736171 | 0.85 | TSHR (0.48) | SMN1; SMN2MEN1KMT2ALMNATSHR | |
| SCHEMBL8958401 | 0.83 | MEN1 (0.52) | SMN1; SMN2MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL9447837 | 0.83 | MEN1 (0.52) | SMN1; SMN2MEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945786-B2 | Compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | SMN1; SMN2 1100/4885MEN1 272/4885KMT2A 4010/4885 |
| US-11945786-B2 | Compounds, devices, and uses thereof | SLC10A1, SLCO1B3, SLC5A1 | SMN1; SMN2 1100/4885MEN1 272/4885KMT2A 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.